Purpose Selinexor is a novel XPO1 inhibitor which inhibits the export of tumor suppressor
proteins and oncoprotein mRNAs, leading to cell-cycle arrest and apoptosis in cancer cells …

Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that
inhibits exportin‐1 (XPO1), a novel therapeutic target that is overexpressed in multiple …

Background CARTITUDE-1 is a phase 1b–2 study evaluating ciltacabtagene autoleucel
(cilta-cel), a chimeric antigen receptor T cell therapy with two B-cell maturation antigen …

Therapy for multiple myeloma (MM), a hematologic neoplasm of plasma cells, has
undergone remarkable changes over the past 25 years. Small molecules (molecular weight …

Objectives This literature review provides an overview of meaningful change thresholds for
the European Organisation for Research and Treatment of Cancer Quality of Life …

Purpose Patients with relapse and/or refractory multiple myeloma (RRMM) have a high
disease burden with poor health-related quality of life (HRQoL) which worsens with each …

Background Patients with multiple myeloma experience severe symptom burden. Patient
participation in self-reporting is essential as medical staff's assessment of patient symptom …

Selinexor is a novel and potentially synergistic therapy for lymphoid malignancies, although
requires refined supportive measures and strategies to improve its efficacy. Likely, for …

Introduction Patients with relapsed or refractory multiple myeloma (RRMM) report
significantly lower HRQoL compared with patients with newly diagnosed MM and …

Gastric cancer is a leading cause of cancer related deaths worldwide. Throughout the world,
there is around one million new diagnosed cases per year and only an approximate 25 …